Drug intelligence / Profile preview

TOP-0618

Development stage: Preclinical
Lead developer: Naval Medical University
Modality: Small Molecules
Administration: Unknown

Overview

**TOP-0618** is a *homocamptothecin derivative* investigated as a radiosensitizing agent for pancreatic cancer. It enhances tumor cell sensitivity to radiotherapy by inducing G2/M phase cell cycle arrest and promoting apoptosis, thereby improving the efficacy of radiotherapy in preclinical models. The drug has shown cytotoxic effects against pancreatic cancer cell lines and enhances the effect of irradiation, resulting in increased necrosis and apoptosis in xenograft tumor models[1][2].

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on TOP-0618.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOP-0618.

Explore the full profile